Livagen
Also known as: Peptídeo hepático
Molecular Identifiers
Overview
Hepatic bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in hepatocytes and supports liver function, including detoxification processes. Used in short cycles for hepatic protection and regeneration.
KEWD Lys-Glu-Trp-Asp Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in hepatocytes
- Support for hepatic function and detoxification capacity
- Normalization of hepatic protein and lipid metabolism
- Modulation of hepatic tissue regeneration
- Bioregulatory effect on hepatobiliary function
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day via subcutaneous injection |
| Frequency | Once daily |
| Timing | Morning or as per protocol |
| Duration | 10-20 days, cycled 2-4 times per year |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Presentations & Preparation
Vials of Livagen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Livagen.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily